Your browser doesn't support javascript.
The Efficacy of Convalescent Plasma Use in Critically Ill COVID-19 Patients.
Tirnea, Livius; Bratosin, Felix; Vidican, Iulia; Cerbu, Bianca; Turaiche, Mirela; Timircan, Madalina; Margan, Madalin-Marius; Marincu, Iosif.
  • Tirnea L; Department of Infectious Diseases, "Victor Babes" University of Medicine and Pharmacy, 300041 Timisoara, Romania.
  • Bratosin F; Department of Infectious Diseases, "Victor Babes" University of Medicine and Pharmacy, 300041 Timisoara, Romania.
  • Vidican I; Department of Infectious Diseases, "Victor Babes" University of Medicine and Pharmacy, 300041 Timisoara, Romania.
  • Cerbu B; Department of Infectious Diseases, "Victor Babes" University of Medicine and Pharmacy, 300041 Timisoara, Romania.
  • Turaiche M; Department of Infectious Diseases, "Victor Babes" University of Medicine and Pharmacy, 300041 Timisoara, Romania.
  • Timircan M; Department of Gynecology, "Victor Babes" University of Medicine and Pharmacy, 300041 Timisoara, Romania.
  • Margan MM; "Victor Babes" University of Medicine and Pharmacy, 300041 Timisoara, Romania.
  • Marincu I; Department of Infectious Diseases, "Victor Babes" University of Medicine and Pharmacy, 300041 Timisoara, Romania.
Medicina (Kaunas) ; 57(3)2021 Mar 11.
Article in English | MEDLINE | ID: covidwho-1124742
Semantic information from SemMedBD (by NLM)
1. COVID-19 PROCESS_OF Patients
Subject
COVID-19
Predicate
PROCESS_OF
Object
Patients
2. Critical Illness PROCESS_OF Patients
Subject
Critical Illness
Predicate
PROCESS_OF
Object
Patients
3. 2019 novel coronavirus PROCESS_OF Patients
Subject
2019 novel coronavirus
Predicate
PROCESS_OF
Object
Patients
4. COVID-19 PROCESS_OF Patients
Subject
COVID-19
Predicate
PROCESS_OF
Object
Patients
5. Critical Illness PROCESS_OF Patients
Subject
Critical Illness
Predicate
PROCESS_OF
Object
Patients
6. 2019 novel coronavirus PROCESS_OF Patients
Subject
2019 novel coronavirus
Predicate
PROCESS_OF
Object
Patients
ABSTRACT
Background and

Objectives:

On 24 March 2020, the United States Food and Drug Administration (FDA) announced the approval of convalescent plasma therapy for critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as an emergency investigational new drug. This pilot study from Romania aimed to determine if convalescent plasma transfusion can be beneficial in the treatment of selected critically ill patients diagnosed with a SARS-CoV-2 infection. Materials and

Methods:

Donor and receiver eligibility for critically ill coronavirus disease 2019 (COVID-19) patients was based on Romanian guidelines issued at the time of the study. Here, we describe the evolution of a total of five eligible patients diagnosed with COVID-19 who received convalescent plasma (CP) in Romania.

Results:

In spite of our efforts and convalescent plasma administration, three of the five patients did not survive, while the other two recovered completely. Over the course of our five-day laboratory record, the surviving patients had significantly lower values for C-reactive protein, interleukin-6, and white blood cells.

Conclusions:

This pilot study provides insufficient evidence to determine the efficacy of convalescent plasma use as a therapeutic option for critically ill COVID-19 patients.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Clinical Practice Guide Limits: Adult / Humans / Male / Middle aged Country/Region as subject: Europa Language: English Journal subject: Medicine Year: 2021 Document Type: Article Affiliation country: Medicina57030257

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Clinical Practice Guide Limits: Adult / Humans / Male / Middle aged Country/Region as subject: Europa Language: English Journal subject: Medicine Year: 2021 Document Type: Article Affiliation country: Medicina57030257